Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses

Oncogene volume 24, pages 7792–7801 (2005)Cite this article

Abstract

Oncolytic adenoviruses have been considered for use as anticancer therapy for decades, and numerous means of conferring tumor selectivity have been developed. As with any new therapy, the trip from the laboratory bench to the clinic has revealed a number of significant development hurdles. Viral therapies are subject to specific regulations and must meet a variety of well-defined criteria for purity, potency, stability, and product characterization prior to their use in the clinic. Published regulatory guidelines, although developed specifically for biotechnology-derived products, are applicable to the production of oncolytic adenoviruses and other cell-based products, and they should be consulted early during development. Most importantly, both the manufacturing process and the development of characterization and release assays should be science-driven, use the best available science and technology, and must consider the unique nature of the product: a living, and mutatable, virus. Potentially significant impacts on product quality and safety stem from the possibility of genetic instability related to over-engineering the viruses (as evidenced by their recombination and/or occasional reversion to wild-type virus during manufacturing). This report provides examples of some of the critical components affecting the development and production of clinical grade material and summarizes the significant progress made in recent years.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Alemany RC and Curiel DT . (2001). Gene Therapy, 8, 1347–1353.

  • Alemany RC, Lai S, Lou YC, Jan HY, Fang X and Zhang WW . (1999). Cancer Gene Ther., 6, 21–25.

  • Bernt RM, Liang M, Ye X, Ni S, Li ZY, Ye SL, Hu F and Lieber A . (2002). J. Virol., 76, 10994–11002.

  • Biederer C, Reis S, Brandts CH and McCormick F . (2002). J. Mol. Med., 80, 163–175.

  • Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F . (1996). Science, 274, 373–376.

  • Bristol JA, Zhu M, Ji H, Mina M, Xie Y, Clarke L, Forry-Schaudies S and Ennist DL . (2003). Mol. Ther., 7, 755–764.

  • Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, Krasnykh and Curiel DT . (1999). Nat. Biotechnol., 17, 470–475.

  • Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D and Hoeben RC . (1998). Hum. Gene Ther., 9, 1909–1917.

  • Farson D, Tao L, Ko D, Harding T, Li Q, Brignetti D, Yu DC and Li Y . (2005). Proceedings of American Society of Gene Therapy Annual Meeting. St Louis, MO, USA.

  • Farson D, Tao L, Ko D, Harding T, Yu DC and Li Y . (2004). Proceedings of American Society of Gene Therapy Annual Meeting. Minneapolis, MN, USA.

  • Freytag SO, Rogulski KR, Paielli DL, Gilbert JD and Kim JH . (1998). Hum. Gene Ther., 9, 1323–1333.

  • Graham FL, Smiley J, Russell WC and Nairn R . (1977). J. Gen. Virol., 36, 59–74.

  • Haviv YS and Curiel DT . (2003). Curr. Gene Ther., 3, 357–385.

  • Hehir KM, Armentano D, Cardoza LM, Choquette TL, Berthelette PB, White GA, Couture LA, Everton MB, Keegan J, Martin JM, Pratt DA, Smith MP, Smith AE and Wadsworth S . (1996). J. Virol., 70, 8459–8467.

  • Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L and Kirn D . (2000). Nat. Med., 6, 1134–1139.

  • Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R and Curiel DT . (2001). Cancer Res., 61, 6377–6381.

  • Henderson D, Chen Y and Yu D . (2001). Replication-Competent Viruses for Cancer Therapy. Hernaiz Driever P and Rabkin SD (eds). Karger: Basel, pp. 56–80.

    Book  Google Scholar 

  • Henderson D and Yu D . (2002). Adenoviral Vectors for Gene Therapy. Curiel D and Douglas J (eds). Academic Press: San Diego, pp. 287–319.

    Book  Google Scholar 

  • Johnson L . (2002). Cancer Cell, 1, 325–337.

  • Jones SD and Levine HL . (2004). Preclinica, 2, 301–304.

  • Kirn D . (2001). Gene Therapy, 8, 89–98.

  • Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao YF, Miyazono K, Urabe A and Takaku F . (1989). J. Cell Physiol., 140, 323–334.

  • Lusky M . (2005). Hum. Gene Ther., 16, 281–291.

  • Murakami P, Havenga M, Fawaz F, Vogels R, Marzio G, Pungor E, Files J, Do L, Goudsmit J and McCaman M . (2004). J. Virol., 78, 6200–6208.

  • Murakami P, Pungor E, Files J, Do L, Van Rijnsoever R, Vogels R, Bout A and McCaman M . (2002). Hum. Gene Ther., 13, 909–920.

  • O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D and McCormick F . (2004). Cancer Cell, 6, 611–623.

  • Reid T, Warren R and Kirn D . (2002). Cancer Gene Ther., 9, 979–986.

  • Ryan PC, Jakubczak JL, Stewart DA, Hawkins LK, Cheng C, Clarke LM, Ganesh S, Hay C, Huang Y, Kaloss M, Marinov A, Phipps SS, Reddy PS, Shirley PS, Skripchenko Y, Xu L, Yang J, Forry-Schaudies S and Hallenbeck PL . (2004). Cancer Gene Ther., 11, 555–569.

  • Shen Y . (2003). Twelfth International Conference on Gene Therapy of Cancer. San Diego, CA, USA.

  • Smith JG and Eck SL . (1999). Cancer Gene Ther., 6, 475–481.

  • Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT and Alemany R . (2001). Clin. Cancer Res., 7, 120–126.

  • Wakimoto H, Johnson PR, Knipe DM and Chiocca EA . (2003). Gene Therapy, 10, 983–990.

  • Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, Nguyen N, Amin P, Oh J and Henderson DR . (2001). Cancer Res., 61, 517–525.

  • Yu DC, Chen Y, Seng M, Dilley J and Henderson DR . (1999). Cancer Res., 59, 4200–4203.

  • Yu DC, Working PK and Ando D . (2002). Curr. Opin. Mol. Ther., 4, 435–443.

Download references

Author information

Authors and Affiliations

  1. Cell Genesys, Inc., 500 Forbes Boulevard, South San Francisco, 94080, CA, USA

    Peter K Working, Andy Lin & Flavia Borellini

Authors
  1. Peter K Working
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andy Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Flavia Borellini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter K Working.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Working, P., Lin, A. & Borellini, F. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses. Oncogene 24, 7792–7801 (2005). https://doi.org/10.1038/sj.onc.1209045

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209045

Keywords

This article is cited by

Search

Advanced search

Quick links